Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,553 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

NCT03161015
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

NCT02199574
View directory record Official record
Conditions
Pain
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Desogestrel-containing COCP Pharmacokinetic Validation Study

NCT05002738
View directory record Official record
Conditions
Contraception
Interventions
Desogestrel and Ethinyl Estradiol Tablets
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 27, 2026, 3:52 PM EDT
Terminated Phase 1 Interventional

Rosuvastatin Interethnic PK Study

NCT02215174
View directory record Official record
Conditions
Statin Pharmacokinetics Pre and Post Gastric Bypass Surgery
Interventions
Rosuvastatin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Not applicable Interventional

A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease

NCT00035074
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Methotrexate
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers

NCT01587313
View directory record Official record
Conditions
Healthy
Interventions
Isosorbide dinitrate / hydralazine capsules
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 27, 2026, 3:52 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

NCT07287033
View directory record Official record
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 3:52 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07047716
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis
Interventions
Lenacapavir Injection, Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

NCT01279538
View directory record Official record
Conditions
Kidney Transplantation
Interventions
bleselumab, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 2 Interventional

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04569435
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

NCT01280240
View directory record Official record
Conditions
Patients With Chemotherapy Induced Anemia (CIA)
Interventions
Monofer(R)
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Baltimore, MD, Maryland • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

NCT00020150
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
O6-benzylguanine, temozolomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Study of FCN-437c in Patients With Advanced Solid Tumors

NCT03951116
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FCN-437
Drug
Lead sponsor
Fochon Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Duarte, California • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

NCT01219855
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions
Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 27, 2026, 3:52 PM EDT
Not listed Phase 1Phase 2 Interventional

IMX-110 in Patients With Advanced Solid Tumors

NCT03382340
View directory record Official record
Conditions
Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer, Ovarian Cancer
Interventions
Imx-110
Drug
Lead sponsor
Immix Biopharma Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Administration of BIIB028 to Subjects With Solid Tumors

NCT00725933
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BIIB028
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Encinitas, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 27, 2026, 3:52 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

NCT05561374
View directory record Official record
Conditions
High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
Interventions
Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Santa Monica, California • Louisville, Kentucky • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

NCT04572685
View directory record Official record
Conditions
Schizophrenia Patients
Interventions
Paliperidone Palmitate
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 27, 2026, 3:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DYNE-251, Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
4 Years to 16 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

NCT01094860
View directory record Official record
Conditions
Leukemia
Interventions
Nelarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 27, 2026, 3:52 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Cigarette Harm Reduction With Electronic Cigarette Use

NCT03473483
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Toxicity, Nicotine Dependence, Cigarettes, Cardiovascular Risk Factor, Nicotine Withdrawal
Interventions
SREC
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 27, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

NCT03939702
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 27, 2026, 3:52 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 27, 2026, 3:52 PM EDT